



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017

Tel. : 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • CIN : L24233MP1985PLC002709

Date: 15.05.2015

To,
The General Manager-Listing
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001(M.H.)

To,
The General Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

SUB: CODE OF FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

Dear Sirs,

Pursuant to Regulation 8 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 the Board of Directors at its meeting held on 30th March, 2015 formulated and adopted the "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" (Code of Fair Disclosure) of the Company which will be effective from today i.e. 15th May, 2015. The Code is enclosed herewith for your records.

Further, the Board has also formulated and adopted "Code of Conduct for Prohibition of Insider Trading" (Code of Conduct) of the Company as prescribed under Regulation 9 of the said Regulations.

Kindly take note of the same.

Thanking You
Yours faithfully
For BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah
Managing Director



BCPL Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information

This document forms the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information ("Code") adopted by **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** (BCPL). This Code is consistent with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The Principles of Fair Disclosure adopted by BCPL are as follows:

1. The Company shall make promptly public disclosure of unpublished price sensitive information that would impact price discovery. Such disclosures are made no sooner than credible and concrete information comes into being in order to make such information generally available.
2. The Company shall ensure disclosures of unpublished price sensitive information, as and when made, in a universal and uniform manner through forums like widely circulated media and / or through stock exchanges where its equity shares are listed. Selective disclosure of unpublished price sensitive information is to be avoided.
3. BCPL Chief Financial Officer serves as its Chief Investor Relations Officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
4. The Company will make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise if at all, to make such information generally available.
5. The company will ensure appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
6. The Company will ensure that information shared with analysts and research personnel is not unpublished price sensitive information.
7. The Company will publish proceedings of meetings with analysts and of other investor relations conferences on its official website www.biofilgroup.net to ensure official confirmation and documentation of disclosures made therein.
8. The Company shall handle all unpublished price sensitive information on a need-to-know basis only.

The code is subject to review from time to time.


Ramesh Shah
Managing Director

